Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pharmacokinetic Comparability Study of a Commercial Supply of Eptinezumab

Trial Profile

A Pharmacokinetic Comparability Study of a Commercial Supply of Eptinezumab

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eptinezumab (Primary)
  • Indications Migraine
  • Focus Pharmacokinetics
  • Acronyms ALD403-CLIN-014
  • Most Recent Events

    • 22 Feb 2019 According to an Alder Biopharmaceuticals media release, based on the data from PROMISE 1, PROMISE 2 and an open-label safety study, company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for eptinezumab.
    • 23 Oct 2018 Results published in the Alder Biopharmaceuticals Media Release
    • 23 Oct 2018 According to an Alder Biopharmaceuticals Media Release,Status changed from planning to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top